744 related articles for article (PubMed ID: 31804827)
21. Targeting steroid hormone receptors for ubiquitination and degradation in breast and prostate cancer.
Rodriguez-Gonzalez A; Cyrus K; Salcius M; Kim K; Crews CM; Deshaies RJ; Sakamoto KM
Oncogene; 2008 Dec; 27(57):7201-11. PubMed ID: 18794799
[TBL] [Abstract][Full Text] [Related]
22. Design, synthesis and activity study of a novel PI3K degradation by hijacking VHL E3 ubiquitin ligase.
Wang H; Li C; Liu X; Ma M
Bioorg Med Chem; 2022 May; 61():116707. PubMed ID: 35344835
[TBL] [Abstract][Full Text] [Related]
23. Chimeric molecules facilitate the degradation of androgen receptors and repress the growth of LNCaP cells.
Tang YQ; Han BM; Yao XQ; Hong Y; Wang Y; Zhao FJ; Yu SQ; Sun XW; Xia SJ
Asian J Androl; 2009 Jan; 11(1):119-26. PubMed ID: 19050678
[TBL] [Abstract][Full Text] [Related]
24. An Overview of Next-Generation Androgen Receptor-Targeted Therapeutics in Development for the Treatment of Prostate Cancer.
Mohler ML; Sikdar A; Ponnusamy S; Hwang DJ; He Y; Miller DD; Narayanan R
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33672769
[TBL] [Abstract][Full Text] [Related]
25. Galeterone prevents androgen receptor binding to chromatin and enhances degradation of mutant androgen receptor.
Yu Z; Cai C; Gao S; Simon NI; Shen HC; Balk SP
Clin Cancer Res; 2014 Aug; 20(15):4075-85. PubMed ID: 24874833
[TBL] [Abstract][Full Text] [Related]
26. In silico discovery of androgen receptor antagonists with activity in castration resistant prostate cancer.
Shen HC; Shanmugasundaram K; Simon NI; Cai C; Wang H; Chen S; Balk SP; Rigby AC
Mol Endocrinol; 2012 Nov; 26(11):1836-46. PubMed ID: 23023563
[TBL] [Abstract][Full Text] [Related]
27. Targeted protein degradation and the enzymology of degraders.
Fisher SL; Phillips AJ
Curr Opin Chem Biol; 2018 Jun; 44():47-55. PubMed ID: 29885948
[TBL] [Abstract][Full Text] [Related]
28. The design, synthesis and bioactivity evaluation of novel androgen receptor degraders based on hydrophobic tagging.
Sun Y; Wang H; Li Y; Li Z; Mao Z; Zhang M; Shao Y; Ye J; Li D; Shan L
Bioorg Chem; 2024 May; 146():107309. PubMed ID: 38537338
[TBL] [Abstract][Full Text] [Related]
29. Development of Novel Inhibitors Targeting the D-Box of the DNA Binding Domain of Androgen Receptor.
Radaeva M; Ban F; Zhang F; LeBlanc E; Lallous N; Rennie PS; Gleave ME; Cherkasov A
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33801338
[TBL] [Abstract][Full Text] [Related]
30. Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase.
Smith BE; Wang SL; Jaime-Figueroa S; Harbin A; Wang J; Hamman BD; Crews CM
Nat Commun; 2019 Jan; 10(1):131. PubMed ID: 30631068
[TBL] [Abstract][Full Text] [Related]
31. Identification of novel androgen receptor degrading agents to treat advanced prostate cancer.
Wu H; Ren J; Zhao L; Li Z; Ye W; Yang Y; Wang J; Bian J
Eur J Med Chem; 2021 May; 217():113376. PubMed ID: 33756125
[TBL] [Abstract][Full Text] [Related]
32. Discovery of CBPD-409 as a Highly Potent, Selective, and Orally Efficacious CBP/p300 PROTAC Degrader for the Treatment of Advanced Prostate Cancer.
Chen Z; Wang M; Wu D; Zhao L; Metwally H; Jiang W; Wang Y; Bai L; McEachern D; Luo J; Wang M; Li Q; Matvekas A; Wen B; Sun D; Chinnaiyan AM; Wang S
J Med Chem; 2024 Apr; 67(7):5351-5372. PubMed ID: 38530938
[TBL] [Abstract][Full Text] [Related]
33. Effects of MTX-23, a Novel PROTAC of Androgen Receptor Splice Variant-7 and Androgen Receptor, on CRPC Resistant to Second-Line Antiandrogen Therapy.
Lee GT; Nagaya N; Desantis J; Madura K; Sabaawy HE; Kim WJ; Vaz RJ; Cruciani G; Kim IY
Mol Cancer Ther; 2021 Mar; 20(3):490-499. PubMed ID: 33277442
[TBL] [Abstract][Full Text] [Related]
34. Expanding the ligand spaces for E3 ligases for the design of protein degraders.
Shah Zaib Saleem R; Schwalm MP; Knapp S
Bioorg Med Chem; 2024 May; 105():117718. PubMed ID: 38621319
[TBL] [Abstract][Full Text] [Related]
35. Discovery of novel biphenyl derivatives as androgen receptor degraders for the treatment of enzalutamide-resistant prostate cancer.
Zhang W; Fan Y; Zhang Y; Feng Y; Luo Y; Zhou X; Chen Z; Wang C; Lu T; Tang F; Chen Y; Li H; Jiao Y
Bioorg Chem; 2024 Jul; 148():107433. PubMed ID: 38754311
[TBL] [Abstract][Full Text] [Related]
36. Induced protein degradation of anaplastic lymphoma kinase (ALK) by proteolysis targeting chimera (PROTAC).
Kang CH; Lee DH; Lee CO; Du Ha J; Park CH; Hwang JY
Biochem Biophys Res Commun; 2018 Oct; 505(2):542-547. PubMed ID: 30274779
[TBL] [Abstract][Full Text] [Related]
37. Design and characterization of cereblon-mediated androgen receptor proteolysis-targeting chimeras.
Takwale AD; Jo SH; Jeon YU; Kim HS; Shin CH; Lee HK; Ahn S; Lee CO; Du Ha J; Kim JH; Hwang JY
Eur J Med Chem; 2020 Dec; 208():112769. PubMed ID: 32961381
[TBL] [Abstract][Full Text] [Related]
38. Chemical approaches to targeted protein degradation through modulation of the ubiquitin-proteasome pathway.
Collins I; Wang H; Caldwell JJ; Chopra R
Biochem J; 2017 Mar; 474(7):1127-1147. PubMed ID: 28298557
[TBL] [Abstract][Full Text] [Related]
39. Expanding the Structural Diversity at the Phenylene Core of Ligands for the von Hippel-Lindau E3 Ubiquitin Ligase: Development of Highly Potent Hypoxia-Inducible Factor-1α Stabilizers.
Vu LP; Diehl CJ; Casement R; Bond AG; Steinebach C; Strašek N; Bricelj A; Perdih A; Schnakenburg G; Sosič I; Ciulli A; Gütschow M
J Med Chem; 2023 Sep; 66(18):12776-12811. PubMed ID: 37708384
[TBL] [Abstract][Full Text] [Related]
40. Potent and Selective Mitogen-Activated Protein Kinase Kinase 1/2 (MEK1/2) Heterobifunctional Small-molecule Degraders.
Hu J; Wei J; Yim H; Wang L; Xie L; Jin MS; Kabir M; Qin L; Chen X; Liu J; Jin J
J Med Chem; 2020 Dec; 63(24):15883-15905. PubMed ID: 33284613
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]